Sandia Biotech

Executive Summary

Sandia Biotech is a US-based biotechnology company founded in 2019 and headquartered in Albuquerque, New Mexico. The company develops and sells advanced fluorescent antibody reagents, known as FluorAbodies, for research and diagnostic applications. Its core technology aims to provide more consistent, quantifiable, and efficient staining solutions compared to traditional monoclonal antibodies. By leveraging a novel protein engineering platform, Sandia Biotech produces reagents with enhanced brightness, stability, and lot-to-lot reproducibility, addressing key pain points in immunofluorescence workflows. The company targets both academic research labs and commercial diagnostic kit manufacturers, offering a differentiated value proposition in the rapidly growing antibody market.

Upcoming Catalysts (preview)

• Q4 2026Launch of expanded FluorAbody product line targeting new disease areas70% success
• H1 2027Strategic distribution partnership with a major life sciences supplier50% success
• Q3 2026Completion of Series A funding round to scale manufacturing and sales60% success